Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-02
Schmid Timothy Files Johnson & Johnson (JNJ) Form 4 - September 02, 2026
Schmid Timothy traded 67.2K JNJ shares worth $14.1M in this Form 4 filing, reported to the SEC on 2026-09-02.
- Insider
- Schmid Timothy
- Issuer
- Johnson & Johnson JNJ · NYSE
- Filed
- Period
- 2026-09-02
- Accession
- 0000200406-26-000179
- Source
- Official filing on sec.gov ↗
Transactions (6)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Schmid Timothy | 2026-09-02 | Buy | 11.1K | $131.94 | $1.5M | Direct |
| Schmid Timothy | 2026-09-02 | Sell | 11.1K | $274.74 | $3.0M | Direct |
| Schmid Timothy | 2026-09-02 | Buy | 22.5K | $151.41 | $3.4M | Direct |
| Schmid Timothy | 2026-09-02 | Sell | 22.5K | $274.74 | $6.2M | Direct |
| Net change | 0 | −$4.4M | ||||
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Track JNJ insider activity
Get alerted when Johnson & Johnson executives buy or sell their shares.